利奈唑胺耐药性万古霉素耐药性肠球菌的预测因子和结局：病例对照研究。
Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-case-control study.
机构信息
Division of Infectious Diseases, Wayne State University, Detroit Medical Center, Detroit, MI 48201, USA.
出版信息
Am J Infect Control. 2012 Dec;40(10):e261-3. doi: 10.1016/j.ajic.2012.06.009.
Linezolid is an important agent for the treatment of infections because of vancomycin-resistant Enterococcus (VRE). This study identified independent predictors for isolation of linezolid-resistant VRE (LZD-R-VRE) and analyzed outcomes associated with linezolid resistance. Immunosuppression, prior surgery, and previous exposure to β-lactam antibiotics were independent predictors for isolation of LZD-R-VRE but not for LZD-susceptible-VRE. Prior exposure to linezolid was not a predictor for isolation of LZD-R-VRE.
利奈唑胺是治疗耐万古霉素肠球菌（VRE）感染的重要药物。本研究确定了耐利奈唑胺 VRE（LZD-R-VRE）分离的独立预测因素，并分析了与利奈唑胺耐药相关的结果。免疫抑制、既往手术和β-内酰胺类抗生素的既往暴露是 LZD-R-VRE 分离的独立预测因素，但不是 LZD 敏感-VRE 分离的独立预测因素。既往暴露于利奈唑胺不是 LZD-R-VRE 分离的预测因素。
Zotero 插件